Show Notes
Host: Christopher L. Camp, M.D., Creator & Guide | Mayo Clinic Human Optimization Project
Guest: Amy Morin, LCSW, Psychotherapist / Mental Strength Coach / International Bestselling Author | Mentally Strong
One of the biggest limiters of our mental strength is our very common (usually unintentional) struggle with self-sabotaging behaviors. Since we all feel too busy to do more, maybe the answer is to actually do less? For some behaviors, that is absolutely the case. To help us better understand how we can do less, and be better for it, our expert guest for this episode is bestselling author, Amy Morin.
The three big questions she is going to answer for us today are:
What exactly is “mental strength?”
What are the things we are doing that commonly sabotage our mental strength
How can we remove these things from our lives in order to maximize our mental strength?
Learn more about the Human Optimization Project at: https://ce.mayo.edu/optimize
More from Tomorrow's Cure
How could Mayo Clinic’s Global AI Platform transform personalized care?
What if transplant patients could one day live free from lifelong anti-rejection drugs?
What happens when multiple sclerosis symptoms mask a different condition?
What if repairing damaged cartilage could be done in a single procedure? Using your own cells and the healing signals they need to recover?
What if the milk you are drinking could help fight cancer? In this episode of Tomorrow's Cure, we explore cholangiocarcinoma and a surprising new approach to targeting it using milk‑derived nanoparticles and precision aptamer‑based delivery. Host Lindsey Seavert is joined by surgical oncologist Dr. Rory Smoot and long‑term survivor and advocate Melinda Bachini to unpack why this cancer is so challenging, what symptoms and treatment paths patients typically face, and how emerging gene‑delivery platforms and AI‑driven discovery are opening new possibilities when standard therapies fall short. Through Melinda’s 16‑year survivorship story and Dr. Smoot’s lab work that literally starts with skim milk from the Mayo Clinic cafeteria, listeners hear how “chemical antibodies” called aptamers can act as molecular keys to deliver therapy directly to cholangiocarcinoma cells, and how computational tools are accelerating the search for new targets. Together, they discuss the emotional and practical realities of living at the edge of what medicine can do today, the expanding landscape of clinical trials, and why innovation in this rare cancer may ripple out to colon, lung and other hard‑to‑treat tumors.